ReviewCurrent treatment options in neurology2018
Restless Legs Syndrome and Other Movement Disorders of Sleep-Treatment Update.
Review in Current treatment options in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Effects of Dietary Supplementation in Patients with Restless Legs Syndrome: A Systematic Review.Nutrients · 2024Pooled it
- Behavioral and psychological treatments for NREM parasomnias: A systematic review.Sleep medicine · 2023Pooled it
- Large genome-wide association study identifies three novel risk variants for restless legs syndrome.Communications biology · 2020Pooled it
- Restless Legs Syndrome in Hemodialysis Patients: Clinical and Electrophysiological Study.Journal of multidisciplinary healthcare · 2024Article
- Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- A simple mechanistic terminology of psychoactive drugs: a proposal.Naunyn-Schmiedeberg's archives of pharmacology · 2020Review
- Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome.Journal of sleep research · 2020Article
- Neurologic Manifestations of Systemic Disease: Sleep Disorders.Current treatment options in neurology · 2020Review
- Use of botulinum toxin for movement disorders.Drugs in context · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review article is to summarize and discuss the recent advances in the treatment of restless legs syndrome (RLS), as well as REM sleep behavior disorder (RBD), and periodic leg movement disorder (PLMD). RECENT
findingsTraditionally, dopaminergic therapy has been considered the sole option for first-line treatment of RLS due to their impressive acute efficacy. Dopamine agonists such as oral pramipexole and ropinirole, as well as transdermal rotigotine are all effective treatment options. However, augmentation of the RLS symptoms is a major limitation of oral dopaminergic therapy. Recently, gabapentinoid agents such as gabapentin enacarbil and pregabalin have shown comparable short-term efficacy to dopaminergics with lower risk of augmentation of the RLS symptoms. Recent evidence on the efficacy of oxycodone-naloxone in treatment-resistant RLS provides an additional therapeutic avenue. The increasing understanding of the role of iron in RLS pathophysiology has led to new options in iron supplementation therapy in RLS, including treatment with ferric carboxymaltose. With emerging evidence of augmentation being a side effect specific to dopaminergic treatment, gabapentinoids are considered a safer option as initial treatment. In severe refractory RLS, oxycodone-naloxone can be used. If iron stores are low, IV iron formulations should be the initial treatment choice. New treatment options are needed to address issues with current therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.